However, the use of the low-dose regimen did not exhibit a significant beneficial effect on nausea (OR = 0.32; 95% CI, 0.04–2.72; I2 = 50%; P = 0.29), leukopenia (OR = 0.38; 95% CI, 0.13–1.36; I2 = 34%; P = 0.14), thrombocytopenia (OR = 0.33; 95% CI, 0.07–1.49; I2 = 51%; P = 0.15), increased ALT levels (OR = 0.89; 95% CI, 0.41–1.95; I2 = 0%; P = 0.77), hyperkalemia (OR = 0.53; 95% CI, 0.26–1.06; I2 = 0%; P = 0.07), and renal injury (OR = 0.67; 95% CI, 0.28–1.59; I2 = 37%; P = 0.37). The gene discussed is GPT; the disease is Thrombocytopenia.